Navigation Links
Sinus Dynamics Announced Treatment for MRSA with Nasal Nebulizer and Vancomycin
Date:10/24/2009

Vancomycin is used to treat bacterial infections by stopping or killing the bacteria responsible. When treatment using other antibiotics has failed, Vancomycin is the strongest option available. Now through Sinus Dynamic , Vancomycin is available in an aerosolized topical form which is effective against MRSA.

Westlake Village, CA (PRWEB) October 22, 2009 -- Sinus Dynamics™ announced today that the company has discovered treatment for Methicillin Resistant Staphylococcus Aureus (MRSA) with a nasally inhaled aerosolized form of Vancomycin, which can help patients and hospitals limit exposure to asymptomatic MRSA carriers.

Pharmacists at Sinus Dynamic can help the medical professionals address one of the largest fears of physicians, hospital administrators and patients alike (Hospital Acquired Infections). The Centers for Disease Control and Prevention estimates that hospital acquired infections are a direct result of 90,000 patient deaths each year in the U.S.A., while other organizations claim that the number is much higher.

Sinus Dynamics is the nation's leading compounding pharmacy specializing exclusively in the research and development of aerosolized formulas to treat bacterial and fungal sinus infections, sinus inflammation, and acute and chronic sinusitis. Sinus Dynamics treatments are self-administered by the patient using a small lightweight, electronic nebulizer. This medical device creates a 3.2 micron medicated mist, consisting of antibiotic, anti-fungal or anti-inflammatory medications. The medicated mist penetrates the sinus cavities to topically treat sinuses infected with MRSA or any other bacterial or fungal infection. With industry leading technology that enables physicians from across the country to prescribe our topical treatment method for their refractory sinus patients; Sinus Dynamics has the experience and resources in place to confront MRSA at its so
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmacy Compounds Liquid Mupirocin for the Chronic Sinusitis Patient
2. SyntheMed Announces FDA Clearance of SinusShield(TM)
3. Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation
4. Cellular Dynamics International Appoints Leroy Hood, M.D., Ph.D., and George Church, Ph.D., to its Scientific Advisory Board
5. Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International
6. Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
7. Cellular Dynamics International Reprograms Blood Cells into Stem Cells
8. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
9. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
10. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
11. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 According ... Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity ... Development, Preclinical, Clinical Trial), by End Users - Global ... is expected to reach USD 2,107.99 million by 2020 ... of 15.29%. Browse more than ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
(Date:7/29/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today ... Financial Officer has resigned.  The Company has hired ... retired in December 2014, as full time interim CFO ... Andy Ashworth began his employment ... smooth transition.  Andy was the Company,s CFO from September ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... and Line of Credit -, NES-ZIONA, Israel, ... a biopharmaceutical company applying its,patented technology to develop ... it has closed a $2 million,equity investment by ... into a,line of credit agreement that provides for ...
... Conference, SAN DIEGO, March 27 SGX Pharmaceuticals,(Nasdaq: ... the SGX523 clinical program., In January 2008, the ... SGX523 in patients with solid tumor cancers. The first,trial ... on a continuous,28-day cycle and the second trial has ...
... Live Webcast and Conference Call Scheduled for Monday, March 31st at 5 PM ... ... 26 ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) today announced that the Company ... Monday, March 31,2008, at 5:00 p.m. ET to discuss corporate updates and financial ...
Cached Biology Technology:Modigene Announces Closing of $12 Million Financing by Members of The Frost Group 2Modigene Announces Closing of $12 Million Financing by Members of The Frost Group 3Modigene Announces Closing of $12 Million Financing by Members of The Frost Group 4Modigene Announces Closing of $12 Million Financing by Members of The Frost Group 5SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials 2SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials 3
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... the growing mobile commerce market announces a revised version of one ... The commercial will air on CNBC in New York ... and San Francisco metro areas. ... focuses on Wocket,s ability to replace all the cards in your ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.65 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Latin America Biomedical Sensors Market Report 2015-2020 2
... could pose a more serious threat to marine life ... Exeter, published today (19 July) in the British Ecological ... tens of thousands of turtles from across the Pacific ... Focusing on fisheries in Peru, the study suggests ...
... a new in vivo screening system, Whitehead Institute researchers ... that is essential in estrogen receptor (ER)-negative breast cancer. ... this proteinphosphoglycerate dehydrogenase or PHGDHis suppressed in tumors and ... rate of cellular growth declines markedly. RELEVANCE: ...
... move across surfaces prior to forming multicellular bacterial biofilms. ... known as "twitching" motility, which is made possible by ... or TFP. "TFP act like Batman,s ... and of chemistry and biochemistry at the UCLA Henry ...
Cached Biology News:Study shows small-scale fisheries' impact on marine life 2Key metabolic pathway implicated in intractable form of breast cancer 2UCLA study shows bacteria use Batman-like grappling hooks to 'slingshot' on surfaces 2
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
Biology Products: